Jazz Pharmaceuticals Says FDA Approved Ziihera Regimens for HER2-Positive Gastroesophageal Cancer

10:24 AM EDT, 08/25/2026 (MT Newswires) -- Jazz Pharmaceuticals (JAZZ) said Tuesday that the US Food and Drug Administration approved two of its Ziihera-containing regimens to treat adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, a type of cancer. The two regimens are Ziihera plus Tevimbra and chemotherapy for all HER2-positive patients, and Ziihera plus chemotherapy alone for those with IHC 3+ disease, the company said. Jazz said that the approval was based on results from its Phase 3 HERIZON-GEA-01 trial, which showed significant improvements in progression-free survival and overall survival. Shares of the company were up 2.5% in early Tuesday trading. Price: 258.76, Change: +4.29, Percent Change: +1.69